StemBioSys Raises $4.3M For New Products

Abstract representation of the stem cell matrix. Source: Gerd Altmann, no changes made, CC0 Creative Commons.
Advertisement img

StemBioSys has closed a $4.3 million Series B round of funding roughly two years after it began fundraising. The company spent much of 2017 launching new branding for its lead product which is now called CELLvo™ Matrix, which is used to replicate stem cells.

StemBioSys manufactures and develops novel, proprietary stem cell technologies to meet the promise of regenerative medicine in a surging global market. Founded in 2010, housed in San Antonio, StemBioSys is led by an experienced management and scientific team.

The company’s novel technology platform is an advanced stem cell culture system the CELLvo™ Matrix. It replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in CELLvo™ Matrix remain small, proliferative and undifferentiated. The technology enables users to isolate and grow stem cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue.

Featured Partners

The CELLvo™ Matrix architecture also enables the isolation and expansion of multi-potent stem cells from human umbilical cord blood (hUCB-SCs). This patent-pending process produces non-differentiated stem cells capable of producing tissues from all 3 developmental germ layers.

The company has documented how the hUCB-SCs, when implanted into experimental animals, produce discrete bundles of various human tissues, including muscle, nerve, bone, adipose and glandular tissues.

The development of novel and proprietary stem cell technologies creates new hope for treating, and in some cases, perhaps even curing, human diseases like diabetes, Alzheimer’s, Parkinson’s, inflammatory disorders, osteoarthritis and damaged cartilage.

StemBioSys Inc. is identifying promising clinical applications as well as collaborators to further develop and license stem cell technologies for research, pharmaceutical and clinical use.

CEO Bob Hutchens says the biotech is spending the money on its commercial capability, to develop new products, and to identify and develop new applications of StemBioSys’ core technology.